TrialCancer immunology, immunotherapy : CII2018

A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.

Jhanelle E Gray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.